State Street Corp Aadi Bioscience, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, State Street Corp holds 68,737 shares of AADI stock, worth $196,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,737

Previous 68,737 -0.0%

Holding current value

$196,587

Previous $100,000 41.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.46 - $2.31 $447,358 - $707,807	-306,410 Reduced 81.68%	68,737 $100,000
Q1 2024 May 15, 2024	BUY	$1.59 - $2.44 $95,778 - $146,980	60,238 Added 19.13%	375,147 $877,000
Q4 2023 Feb 14, 2024	BUY	$1.97 - $5.41 $36,523 - $100,301	18,540 Added 6.26%	314,909 $636,000
Q3 2023 Nov 14, 2023	SELL	$4.84 - $7.13 $8,005 - $11,793	-1,654 Reduced 0.55%	296,369 $1.43 Million
Q2 2023 Aug 14, 2023	BUY	$6.84 - $8.56 $216,677 - $271,163	31,678 Added 11.89%	298,023 $2.04 Million
Q1 2023 May 15, 2023	BUY	$6.85 - $13.0 $2,061 - $3,913	301 Added 0.11%	266,345 $1.93 Million
Q4 2022 Feb 14, 2023	BUY	$11.99 - $14.5 $191,648 - $231,768	15,984 Added 6.39%	266,044 $3.41 Million
Q3 2022 Nov 15, 2022	SELL	$12.03 - $14.22 $3.44 Million - $4.06 Million	-285,554 Reduced 53.31%	250,060 $3.53 Million
Q2 2022 Aug 15, 2022	BUY	$11.57 - $17.92 $416 - $645	36 Added 0.01%	535,614 $6.6 Million
Q1 2022 May 16, 2022	BUY	$16.65 - $24.97 $3.73 Million - $5.6 Million	224,178 Added 71.99%	535,578 $9.09 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $29.02 $6.02 Million - $9.04 Million	311,400 New	311,400 $7.52 Million

Others Institutions Holding AADI

# of Institutions

Shares Held

12.6M

Call Options Held

23.8K

Put Options Held

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $60.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Aadi Bioscience, Inc. Transaction History